William Blair reduced their Q1 2026 EPS estimates for Bristol-Myers Squibb in a research report issued to clients and ...

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

Exelixis, Inc. (NASDAQ:EXEL) authorized repurchasing up to an additional $500 million of the company’s common stock before December 31, 2025. Exelixis plans to complete the $500 million stock ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine ...

Following a lackluster 2024, shares of major drugmakers kicked off 2025 with an upbeat quarterly results reading. U.S. pharmaceuticals like Eli Lilly (LLY), Johnson & Johnson (JNJ), Bristol-Myers ...

Bernstein analyst Courtney Breen maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) yesterday and set a price target of ...

Additional data from CheckMate 274 showed that adjuvant nivolumab benefits patients with muscle-invasive bladder cancer with ...

Shares of Bristol Myers Squibb Co. BMY rose 1.47% to $55.79 Thursday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to ...

Bristol Myers Squibb Co. said Cari Gallman, the company’s executive vice president for corporate affairs, will become its ...